Administration of SB239063 Ameliorates Ovariectomy-Induced Bone Loss via Suppressing Osteoclastogenesis in Mice

Administration of SB239063 Ameliorates Ovariectomy-Induced Bone Loss via Suppressing Osteoclastogenesis in Mice

Activation of osteoclast formation and function is crucial for the development of osteolytic diseases such as osteoporosis. RANKL (receptor activator of nuclear factor-κB ligand) activates NF-κB (nuclear factor κB), MAPK (mitogen-activated protein kinase), and NFATc1 (nuclear factor of activated T-c...

Full description

Bibliographic Details
Main Authors: Bao Huang, Jiasheng Wang, Xuyang Zhang, Ziang Xie, Hao Wu, Junhui Liu, Zhiwei Jie, Xiangde Zhao, An Qin, Shunwu Fan, Jian Chen, Fengdong Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Pharmacology
Subjects:
SB239063
osteoclastogenesis
c-Fos
MEF2C
p38
bone loss
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00900/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00900/full

Similar Items